Chemotherapy for bladder cancer. Systemic treatment with reduced toxicity;Chemotherapie des harnblasenkarzinoms. Systemtherapie mit reduzierter toxizität

Urologe - Ausgabe A

Volumn 42, Issue 11, 2003, Pages 1445-1449

  Gschwend, J E ^a   Simon, J ^a   Volkmer, B ^a   Hautmann, R E ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Bladder cancer; Chemotherapy; Morbidity; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GALLIUM NITRATE; GEMCITABINE; METHOTREXATE; MITOMYCIN C; NUCLEOSIDE DERIVATIVE; PACLITAXEL; VINBLASTINE;

ADVANCED CANCER; AREA UNDER THE CURVE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG MEGADOSE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MONOTHERAPY; NEPHROTOXICITY; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS; DEOXYCYTIDINE; FEASIBILITY STUDIES; HUMANS; NEOPLASM STAGING; PACLITAXEL; PALLIATIVE CARE; URINARY BLADDER NEOPLASMS;

EID: 0344665654     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-003-0451-z     Document Type: Review

References (22)

1. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52: 23-47
2. Skinner DG, Daniels JR, Russell CA et al. (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145: 459-464
3. Stöckle M, Meyenburg W, Wellek S et al. (1995) Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 153: 47-52
4. Freiha F, Reese J, Torti FM (1996) A randomised trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle-invasive bladder cancer. J Urol 155: 495-500
5. Sternberg CN, Yagoda A, Scher HI et al. (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403-407
6. Sternberg CN, Yagoda A, Scher HI et al. (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64: 2448-2458
7. Bajorin DF, Dodd PM, Mazumdar M et al. (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17: 3173-3181
8. Scher HI, Norton L (1992) Chemotherapy for urothelial tract malignancies: breaking the deadlock. Semin Surg Oncol 8: 316-341
9. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15: 3394-3398
10. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N (1997) Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15: 3441-3445
11. Lorusso V, Pollera CF, Antimi M et al. (1998) A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34: 1208-1212
12. Roth BJ, Dreicer R, Einhorn LH et al. (1994) Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264-2270
13. Dreicer R, Gustin DM, See WA, Williams RD (1996) Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 156: 1606-1608
14. de Wit R, Kruit WH, Stoter G, de Boer M, Kerger J, Verweij J (1998) Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 78: 1342-1345
15. Waxman J, Barton C (1993) Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 19 (Suppl C): 21-25
16. Yagoda A (1987) Chemotherapy of urothelial tract tumors. Cancer 60 (Suppl 3): 574-585
17. von der Maase H, Hansen SW, Roberts JT et al. (2000). Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077
18. Vaughn DJ, Malkowicz SB, Zoltick B et al. (1998) Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 16: 255-260
19. Zielinski CC, Schnack B, Grbovic M et al. (1998) Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. Br J Cancer 78: 370-374
20. Small EJ, Lew D, Redman BG et al. (2000) Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 18: 2537-2544
21. Carles J, Nogue M, Domenech M et al. (2000) Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 59: 24-27
22. Bellmunt J, de Wit R, Albanell J, Baselga J (2001) A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer 37: 2212-2215